Second mutation in BRAF-mutated melanoma doesn't contribute to resistance

A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true. Read more